Main Street Financial Solutions, LLC Argenx Se Transaction History

Main Street Financial Solutions, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$356.95 - $413.29 $4,283 - $4,959	-12 Reduced 1.3%	912 $359,000
Q4 2023 Feb 08, 2024	BUY	$338.91 - $506.01 $80,999 - $120,936	239 Added 34.89%	924 $351,000
Q3 2023 Nov 02, 2023	SELL	$369.35 - $548.43 $39,889 - $59,230	-108 Reduced 13.62%	685 $336,000
Q2 2023 Aug 04, 2023	SELL	$360.14 - $422.58 $14,765 - $17,325	-41 Reduced 4.92%	793 $309,000
Q1 2023 Apr 20, 2023	BUY	$334.23 - $403.65 $1,671 - $2,018	5 Added 0.6%	834 $310,000
Q4 2022 Feb 07, 2023	BUY	$342.17 - $402.31 $283,658 - $333,514	829 New	829 $314,000
Q2 2022 Jul 27, 2022	SELL	$269.58 - $378.88 $64,429 - $90,552	-239 Reduced 14.04%	1,463 $554,000
Q1 2022 Apr 22, 2022	SELL	$254.45 - $351.06 $4,580 - $6,319	-18 Reduced 1.05%	1,702 $537,000
Q4 2021 Feb 08, 2022	BUY	$272.01 - $353.03 $467,857 - $607,211	1,720 New	1,720 $602,000

432

29.2M

390K

272K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $35.7B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Main Street Financial Solutions, LLC, based on Form 13F filings with the SEC.

Stay updated on Main Street Financial Solutions, LLC with notifications on news.